Ileocolonic release peppermint oil
DrugPeppermint oil, menthae piperitae aetheroleum
NCT Number: NCT02716285
Peppermint oil has shown to be effective in the treatment of Irritable Bowel Syndrome (IBS) symptoms in several meta-analyses. However, the level of evidence is moderate and peppermint oil remains relatively under-used in IBS. Therefore, the investigators will conduct a multicenter randomized, placebo controlled trial to investigate the effects of an eight-week peppermint oil treatment in IBS patients according to current European Medicines Agency (EMA) / US Food and Drug Administration (FDA) guidelines. To improve efficacy and to reduce side effects, the investigators aim to study the use of a new peppermint oil formulation, a colon-targeted-delivery capsule that will release the oil in the (ileo-) colonic region specifically.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 3
Gelderse Vallei Hospital, Ede, Gelderland, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Recurrent abdominal pain, at least 1 day/week for the last 3 months; Symptom onset at least 6 months prior to diagnosis; Associated with two or more of the following:
Exclusion criteria
Peppermint oil, menthae piperitae aetheroleum
Placebo capsule, containing microcrystalline cellulose
Peppermint oil, menthae piperitae aetheroleum
Other names: Tempocol
Time frame: 8 weeks
A responder is defined as a patient who experiences at least a 30 percent decrease in the weekly average of worst daily abdominal pain (measured daily, on an 11 point NRS) compared to baseline weekly average in at least 50 percent of the weeks in which the treatment in given.
Time frame: 8 weeks
A responder is defined as a patient who experiences a weekly relief of 1 or 2 (on a 7 point NRS) in at least 50 percent of the weeks in which treatment is given.
Time frame: 8 weeks
As determined by IBS-SSS (IBS symptom severity scale)
Time frame: 8 weeks
As determined by symptom diary
Time frame: 8 weeks
As determined by IBS-SSS (IBS - symptom severity scale)
Time frame: 8 weeks
As determined by symptom diary
Time frame: 8 weeks
As determined by symptom diary
Time frame: 8 weeks
As determined by symptom diary
Time frame: 8 weeks
As determined by symptom diary
Time frame: 8 weeks
Measured by bristol stool chart
Time frame: 8 weeks, 3 and 6 months
Determined by Production Cost Questionnaire (PCQ) questionnaire
Time frame: 8 weeks, 3 and 6 months
Determined by Medical Cost Questionnaire (MCQ) questionnaire
Time frame: 8 weeks, 3 and 6 months
As determined by Euro-Qol-5D (EQ-5D)
Time frame: 8 weeks, 3 and 6 months
As determined by IBS-Quality of life questionnaire (IBS-QoL)
Time frame: 8 weeks
Number of drugs taken as rescue medication (This is not an intervention)
Time frame: 8 weeks
Determined by daily diary
Time frame: 3 and 6 months after discontinuation of treatment
Time frame: 8 weeks
Maastricht University Medical Center
Other
Acronym: PERSUADE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02551029
Abdominal Pain, Colonic Diseases
Maastricht, Netherlands
View Trial DetailsNCT00006157
Abdominal Pain, Colonic Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT06268717
Abdominal Pain, Alpha-Gal Syndrome
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04428619
Abdominal Pain, Autonomic Nervous System Imbalance
Los Angeles, California, United States
View Trial Details